CNS-targeting pharmacological interventions for the metabolic syndrome.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31380808.
- Also identified by DOI 10.1172/JCI129195 and PMC identifier 6763237.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.
Medical subject headings
- Central Nervous System
- Drug Delivery Systems
- Metabolic Syndrome